53
|
Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, Dejima T, Masuda SI, Shigenaga AI, Maeda A, Mogi M, Ichihara N, Kobayashi Y, Hirawa N, Ishigami T, Toya Y, Yabana M, Horiuchi M, Minamisawa S, Umemura S. Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II–Infused Mice. Hypertension 2010; 55:1157-64. [DOI: 10.1161/hypertensionaha.109.147207] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We cloned a novel molecule interacting with angiotensin II type 1 receptor, which we named ATRAP (for angiotensin II type 1 receptor–associated protein). Previous in vitro studies showed that ATRAP significantly promotes constitutive internalization of the angiotensin II type 1 receptor and further attenuates angiotensin II–mediated hypertrophic responses in cardiomyocytes. The present study was designed to investigate the putative functional role of ATRAP in cardiac hypertrophy by angiotensin II infusion in vivo. We first examined the effect of angiotensin II infusion on endogenous ATRAP expression in the heart of C57BL/6J wild-type mice. The angiotensin II treatment promoted cardiac hypertrophy, concomitant with a significant decrease in cardiac ATRAP expression, but without significant change in cardiac angiotensin II type 1 receptor expression. We hypothesized that a downregulation of the cardiac ATRAP to angiotensin II type 1 receptor ratio is involved in the pathogenesis of cardiac hypertrophy. To examine this hypothesis, we next generated transgenic mice expressing ATRAP specifically in cardiomyocytes under control of the α-myosin heavy chain promoter. In cardiac-specific ATRAP transgenic mice, the development of cardiac hypertrophy, activation of p38 mitogen-activated protein kinase, and expression of hypertrophy-related genes in the context of angiotensin II treatment were completely suppressed, in spite of there being no significant difference in blood pressure on radiotelemetry between the transgenic mice and littermate control mice. These results demonstrate that cardiomyocyte-specific overexpression of ATRAP in vivo abolishes the cardiac hypertrophy provoked by chronic angiotensin II infusion, thereby suggesting ATRAP to be a novel therapeutic target in cardiac hypertrophy.
Collapse
Affiliation(s)
- Hiromichi Wakui
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Kouichi Tamura
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yutaka Tanaka
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Miyuki Matsuda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yunzhe Bai
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Toru Dejima
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Shin-ichiro Masuda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Atsu-ichiro Shigenaga
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Akinobu Maeda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Masaki Mogi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Naoaki Ichihara
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yusuke Kobayashi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Nobuhito Hirawa
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Tomoaki Ishigami
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yoshiyuki Toya
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Machiko Yabana
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Masatsugu Horiuchi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Susumu Minamisawa
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Satoshi Umemura
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| |
Collapse
|
61
|
Fujita T, Mogi M, Min LJ, Iwanami J, Tsukuda K, Sakata A, Okayama H, Iwai M, Nahmias C, Higaki J, Horiuchi M. Attenuation of Cuff-Induced Neointimal Formation by Overexpression of Angiotensin II Type 2 Receptor-Interacting Protein 1. Hypertension 2009; 53:688-93. [DOI: 10.1161/hypertensionaha.108.128140] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recently we have cloned angiotensin II type 2 receptor–interacting protein 1 (ATIP1) as a novel protein that interacts specifically with the C-terminal tail of the angiotensin II type 2 receptor; however, the pathophysiological roles of ATIP1 in vascular remodeling are still unknown. Here, we generated ATIP1-transgenic (ATIP1-Tg) mice expressing mouse ATIP1 and investigated the role of ATIP1 in vascular remodeling using these transgenic mice. ATIP1-Tg mice exhibited no significant difference in blood pressure compared with wild-type (WT) mice. Angiotensin II type 2 receptor mRNA expression in the femoral artery was increased in injured femoral arteries, reaching a peak at 7 days after operation in WT mice, and a similar result of angiotensin II type 2 receptor expression was observed in ATIP1-Tg mice. In ATIP1-Tg mice, neointimal formation of the femoral artery 14 days after cuff placement was significantly smaller than that in WT mice. 5-Bromo-2′-deoxyuridine incorporation was significantly reduced in the injured arteries of ATIP1-Tg mice compared with WT mice. In ATIP1-Tg mice, superoxide anion production and the expression of a proinflammatory cytokine, tumor necrosis factor-α, were markedly attenuated. Moreover, cell proliferative signaling, such as extracellular signal-regulated kinase phosphorylation, was significantly attenuated in ATIP1-Tg mice compared with WT mice. Taken together, these results suggest that ATIP1 plays an important role in cuff-induced vascular remodeling in mice.
Collapse
Affiliation(s)
- Teppei Fujita
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Masaki Mogi
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Li-Juan Min
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Jun Iwanami
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Kana Tsukuda
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Akiko Sakata
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Hideki Okayama
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Masaru Iwai
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Clara Nahmias
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Jitsuo Higaki
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| | - Masatsugu Horiuchi
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (T.F., M.M., L-J.M., J.I., K.T., A.S., M.I., M.H.) and Integrated Medicine and Informatics (H.O., J.H.), Ehime University Graduate School of Medicine, Ehime, Japan; and the Institut Cochin (C.N.), Université Paris Descartes, Paris, France
| |
Collapse
|